argenx (ARGX) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of argenx (NASDAQ:ARGX) in a research report sent to investors on Thursday, The Fly reports. The brokerage issued a buy rating and a $139.00 price objective on the stock.

A number of other equities research analysts have also issued reports on ARGX. Wedbush lifted their target price on argenx from $93.00 to $114.00 and gave the company an outperform rating in a research report on Monday, June 25th. Nomura assumed coverage on argenx in a research report on Friday, June 29th. They issued a buy rating and a $161.00 target price on the stock. Cowen reissued a buy rating on shares of argenx in a research report on Thursday, June 14th. Piper Jaffray Companies reissued an overweight rating and issued a $130.00 target price on shares of argenx in a research report on Thursday, June 7th. Finally, JMP Securities lifted their target price on argenx from $93.00 to $130.00 and gave the company a positive rating in a research report on Monday, June 18th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. argenx has an average rating of Buy and an average target price of $125.14.

Shares of argenx stock opened at $93.78 on Thursday. argenx has a 52-week low of $21.25 and a 52-week high of $103.00.

Several large investors have recently bought and sold shares of ARGX. Aperio Group LLC acquired a new position in shares of argenx during the 1st quarter worth approximately $268,000. US Bancorp DE acquired a new position in shares of argenx during the 1st quarter worth approximately $598,000. Northern Trust Corp acquired a new position in shares of argenx during the 1st quarter worth approximately $896,000. Dimensional Fund Advisors LP acquired a new position in shares of argenx during the 1st quarter worth approximately $498,000. Finally, Citadel Advisors LLC acquired a new position in shares of argenx during the 1st quarter worth approximately $8,671,000. 56.14% of the stock is currently owned by hedge funds and other institutional investors.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Story: Technical Analysis

The Fly

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply